REPL (Replimune Corp) Long-Term Debt

Corporate emblem and logo of Replimune Inc. (REPL)

Replimune Group, Inc. (REPL) is advancing cancer immunotherapy through strategic alliances with pharma behemoths and mergers. The quote characteristic (separate_debt_long) stands at 0.12. Innovation centers in the UK and US are developing melanoma treatments in collaboration with clinics. Share price growth is expected following the completion of final trials and the FDA application, while investors have already priced in current expenditures.

REPL (Replimune Corp) Company Long-Term Debt history from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Replimune Corp (REPL)

- price and consensus price forecast:
Stock Quotes replimune.com|REPL - Price Target Chart
- market capitalization data:
Market Value Replimune|REPL - Total Company Value
- book capitalization data:
Net Assets per Single Share Replimune|REPL - Company Book Value|Market-to-Book Ratio replimune.com|REPL - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio Replimune Group, Inc.|REPL - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Replimune Inc.|REPL - Company Total Debt|Debt to Net Assets Ratio Replimune|REPL - Company Long-Term Debts|Short-Term Debt Volume Replimune
Comprehensive company analysis:REPL (replimune.com)
Mass-produced product of Replimune

This indicator tracks the volume of obligations with a maturity of more than one year, reflecting the long-term financing strategy and the credit load of the business. For Replimune Group, Inc. (REPL), such funds are critical for diversifying the clinical trials of the RP1 platform and mitigating regulatory risks. Analyzing the company's long-term debt structure allows for an assessment of the balance between leveraged capital and investment potential. The stability of this metric confirms the fundamental resilience of the biotech.

Competing companies

immunitybio.com - Company Long-Term Liabilities|IMCR (Immunocore) - Company Long-Term Debt|JANX: Long-Term Debt|Arcus Bio (RCUS) - Company Long-Term Debt|ZYME (Zymeworks Biopharmaceuticals) - Company Long-Term Debt|Company Long-Term Debt TNGX (Tango Therapeutics)|Long-Term Debt iovance.com|IMTX: Company Long-Term Debts|Long-Term Indebtedness Xencor Inc XNCR|CMPX: Company Long-Term Liabilities|LYEL - Long-Term Debt|Company Long-Term Liabilities Innate Pharma S.A. (IPHA)|PYXS - Company Long-Term Loans and Borrowings|cgen.com - Company Long-Term Debts|IOBT (IO Biotech Inc) - Long-Term Debt Volume|Company Long-Term Debt STRO|Company Long-Term Liabilities INKT|Company Long-Term Debt HOWL (Werewolf Therapeutics)|Company Long-Term Liabilities immixbio.com IMMX|Company Long-Term Liabilities ALXO (ALX Oncology Holdings)|cuebiopharma.com - Company Long-Term Debts|PDS Biotechnology Corp (PDSB) - Company Long-Term Debt|SONN: Company Long-Term Indebtedness|Company Long-Term Debt MAIA|Long-Term Debt liminatuspharma.com|LAVA Therapeutics NV - Company Long-Term Liabilities|Long-Term Indebtedness NextCure Inc (NXTC)|Company Long-Term Liabilities Leap Therapeutics, Inc.|Amount of Long-Term Liabilities intensitytherapeutics.com (INTS)|Company Long-Term Debts Sensei Biotherapeutics, Inc.|Company Long-Term Loans and Borrowings therivabio.com TOVX|GRTS (Gritstone Bio) - Company Long-Term Debts|KA: Long-Term Debt|Company Long-Term Debt NexImmune Corp NEXI|Turnstone Biologics Corp. (TSBX) - Company Long-Term Loans and Borrowings|VCNX (Vaccinex, Inc.) - Company Long-Term Debts|Company Long-Term Debts HARP